Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
telomerase
Biotech
GemVax's peptide drug fails phase 2a neurodegenerative trial
Korea's GemVax revealed that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy.
Fraiser Kansteiner
Oct 29, 2024 11:28am
Geron eyes 2024 US launch for MDS drug after phase 3 win
Jan 4, 2023 10:45am
RNA molecule in ALT cancer cells could be their Achilles heel
Sep 19, 2022 3:00pm
